<DOC>
	<DOCNO>NCT02725957</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled , single ascend dose study perform healthy subject . The study include four escalate dose cohort eight ( 8 ) subject cohort . In cohort , eligible subject randomize 3:1 ratio receive single IV administration 9 % trehalose ( Treatment Arm 1 ) placebo ( Treatment Arm 2 ) . All subject , regardless treatment arm assignment , undergo evaluation receive study drug clinic . Each subject continue follow one week post dosing .</brief_summary>
	<brief_title>A Study Establish Safety Maximum Tolerated Dose IV Trehalose Healthy Subjects</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled , single ascend dose study perform healthy subject . The study include four escalate dose cohort eight ( 8 ) subject cohort . In cohort , eligible subject randomize 3:1 ratio receive single IV administration 9 % trehalose ( Treatment Arm 1 ) placebo ( Treatment Arm 2 ) . All subject , regardless treatment arm assignment , undergo evaluation receive study drug clinic . Each subject continue follow one week post dosing . Cohorts 1 3 After subject give cohort complete 1-week follow-up visit ( Visit 4 ) , Safety Review Committee ( SRC ) review safety PK data cohort . If safety concern identify , exposure data support high dose acceptable , SRC approve continuation next cohort ( dose level ) . Cohort 4 Cohort 4 initiate base review safety exposure data first 3 cohort SRC . This cohort perform suggestion exposure safely increase .</detailed_description>
	<criteria>1 . Healthy men woman 18 55 year ( inclusive ) age 2 . Body Mass Index ( BMI ) 19 29.9 kg/m2 ( inclusive ) weigh least 55 kg . 3 . Subjects general good health opinion investigator 4 . Blood pressure heart rate within normal limit 5 . Female subject must negative serum pregnancy test Screening period ( Day 28 1 ) willing able use medically acceptable method birth control postmenopausal . 1 . Diabetes mellitus type 1 2 HbA1c &gt; 5.6 % Screening 2 . History significant medical disorder 3 . Any clinically significant abnormality safety laboratory test Screening period ( Day 28 1 ) 4 . Known contraindication , hypersensitivity and/or allergy trehalose 5 . Any acute illness ( e.g . acute infection ) within 72 hour 6 . Participation another clinical trial drug receive within 3 month prior dose 7 . Positive serum pregnancy test determine Screening period currently lactate woman 8 . ECG clinically significant find recorded Screening period 9 . Positive HIV , Hepatitis B Hepatitis C serology Screening 10 . Known history alcohol drug abuse past 5 year 11 . Positive urinary drug screen determine Screening period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bioblast</keyword>
</DOC>